Cognition Therapeutics CGTX Stock
Cognition Therapeutics Price Chart
Cognition Therapeutics CGTX Financial and Trading Overview
| Cognition Therapeutics stock price | 1.65 USD |
| Previous Close | 1.45 USD |
| Open | 1.46 USD |
| Bid | 1.26 USD x 200 |
| Ask | 1.86 USD x 200 |
| Day's Range | 1.45 - 1.76 USD |
| 52 Week Range | 0.27 - 3.83 USD |
| Volume | 4.02M USD |
| Avg. Volume | 1.33M USD |
| Market Cap | 150.36M USD |
| Beta (5Y Monthly) | 1.751 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.23 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.5 USD |
CGTX Valuation Measures
| Enterprise Value | 119.69M USD |
| Trailing P/E | N/A |
| Forward P/E | -6.0722156 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.014925 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -2.795 |
Trading Information
Cognition Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.751 |
| 52-Week Change | 459.99% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 3.83 USD |
| 52 Week Low | 0.27 USD |
| 50-Day Moving Average | 1.22 USD |
| 200-Day Moving Average | 1.38 USD |
CGTX Share Statistics
| Avg. Volume (3 month) | 1.33M USD |
| Avg. Daily Volume (10-Days) | 1.27M USD |
| Shares Outstanding | 89.5M |
| Float | 81.98M |
| Short Ratio | 7.8 |
| % Held by Insiders | 2.24% |
| % Held by Institutions | 23.48% |
| Shares Short | 6.42M |
| Short % of Float | 7.78% |
| Short % of Shares Outstanding | 7.18% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -89.79% |
| Return on Equity (ttm) | -92.82% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -42820752 USD |
| Net Income Avi to Common (ttm) | -19577000 USD |
| Diluted EPS (ttm) | -0.23 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 31.13M USD |
| Total Cash Per Share (mrq) | 0.35 USD |
| Total Debt (mrq) | 465K USD |
| Total Debt/Equity (mrq) | 1.56 USD |
| Current Ratio (mrq) | 5.917 |
| Book Value Per Share (mrq) | 0.335 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -20253000 USD |
| Levered Free Cash Flow (ttm) | -27778750 USD |
Profile of Cognition Therapeutics
| Country | United States |
| State | NY |
| City | Purchase |
| Address | 2500 Westchester Ave. |
| ZIP | 10577 |
| Phone | 412 481 2210 |
| Website | https://www.cogrx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 14 |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Q&A For Cognition Therapeutics Stock
What is a current CGTX stock price?
Cognition Therapeutics CGTX stock price today per share is 1.65 USD.
How to purchase Cognition Therapeutics stock?
You can buy CGTX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cognition Therapeutics?
The stock symbol or ticker of Cognition Therapeutics is CGTX.
Which industry does the Cognition Therapeutics company belong to?
The Cognition Therapeutics industry is Biotechnology.
How many shares does Cognition Therapeutics have in circulation?
The max supply of Cognition Therapeutics shares is 89.5M.
What is Cognition Therapeutics Price to Earnings Ratio (PE Ratio)?
Cognition Therapeutics PE Ratio is now.
What was Cognition Therapeutics earnings per share over the trailing 12 months (TTM)?
Cognition Therapeutics EPS is -0.23 USD over the trailing 12 months.
Which sector does the Cognition Therapeutics company belong to?
The Cognition Therapeutics sector is Healthcare.
Cognition Therapeutics CGTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
2310.38 USD — |
-1.07
|
— — | 2287.99 USD — | 2333.46 USD — | — - | — — |
- {{ link.label }} {{link}}